EAP-Derived Monoclonal Antibodies for Phenotyping Immune Cells of Animal Model of Disease

EAP 衍生单克隆抗体用于疾病动物模型免疫细胞表型分析

• 批准号: 10933282
• 负责人: MARK GEISBERG
• 金额: $ 75万
• 依托单位: SILVER LAKE RESEARCH CORPORATION
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10933282
• 关键词: Animal Disease Models; Antibodies; Antibody Specificity; Biological Assay; Cells; Communities; Disease model; Homologous Gene; Immune; Industrialization; Inflammation; Label; Monoclonal Antibodies; Phase; Phenotype; Protocols documentation; Reagent; Research; Silver; Testing; Validation; cross reactivity; usability

Silver Lake proposes to fully characterize mAb against 6 targets produced in their three concurrent Phase 1 projects that are relevant in models of disease and inflammation, determine their usability in multiple assay types, develop user protocols for each assay type and mAb, produce quality-controlled reagents, produce multiple conjugates for each mAb, and make all reagents available for the research community.

Silver Lake建议针对在疾病和炎症模型相关的三个同时进行的第一阶段项目中产生的6个靶标充分表征mAb，确定它们在多种检测类型中的可用性，为每种检测类型和mAb开发用户协议，生产质量受控试剂，为每个mAb生产多种结合物，并使所有试剂可供研究界使用。